Bristol-Myers Squibb and Syngene International, India’s largest CRO, have extended their drug discovery and development collaboration in India for another five years. Financial terms were not disclosed.   BMS has been working with Syngene and its parent company, Biocon, since 2007, to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development, at BMS’ Research Ce...